AI-designed anti-aging drug Rentosertib shows human data with six aging clocks pointing younger
rand_longevity · x · 2026-09-09
Rentosertib, an anti-aging drug candidate whose target selection and molecular design were done by AI, has reported human trial data.
- Both target identification and drug design were AI-driven
- Human data reportedly shows six aging clocks trending younger
- The poster highlights it as an exciting milestone for AI in science, marking AI-designed drugs reaching human efficacy evidence
More from Venture
- Quant backgrounds have blind spots in the AI economy, says economist Daniel Rock — soumitrashukla9 · 2026-09-09
- Series B AI CRM firm scrapes job posts to map rivals' CRMs for targeted outreach — MartinGTobias · 2026-09-09
- Series A bar surges: median round up from $4.5M to $19.4M as lead VCs drop to ~50 a year — MartinGTobias · 2026-09-09
- Stanford's Christopher Manning: Silicon Valley has a 'naive belief in gurus', calls AI funding levels 'manifestly crazy' — chrmanning · 2026-09-09
- Three focal points for AI rollup companies: asset selection, talent compensation, and incentive alignment — curious_vii · 2026-09-09
- Ramp data: no-ZDR Fable 5.1 hits 22.5% of enterprise spend, ZDR a hard requirement — zephyr_z9 · 2026-09-09